SERPINE1 and metabolic dysfunction-associated steatotic liver disease: CVD is a leading cause of death in patients with NAFLD and for this reason it remains a focus of tremendous research and clinical interest.69 The body of research about cardiovascular health and exercise in patients with NAFLD and NASH relates to the improvement of CVD biomarkers including improvements in endothelial dysfunction and changes in serum plasminogen activator inhibitor-1 concentration.